To join this case, fill out the form below
Dicerna Pharmaceuticals, Inc. Investigation
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Dicerna Pharmaceuticals, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dicerna Pharmaceuticals, Inc. (“Dicerna” or the “Company”) (NASDAQ: DRNA) in connection with the proposed acquisition of the Company by Novo Nordisk.  Under the terms of the merger agreement, the Company’s shareholders will receive $38.25 per share in cash for each share of Dicerna common stock that they hold.  The all-cash transaction is valued at $3.3billion.

WeissLaw LLP is investigating whether (i) Dicerna’s board of directors acted in the best interest of Dicerna’s shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Dicerna’s shareholders, and (iii) whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed.

‍

Other Cases

April 4, 2024

Doma Holdings Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Doma Holdings Inc. (“Doma” or the “Company”) (NYSE: DOMA), in connection with its acquisition by Title Resources Group. Under the merger agreement, the Company’s shareholders will receive $6.29 per share.

Join Case →

April 4, 2024

Fusion Pharmaceuticals Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Fusion Pharmaceuticals Inc. (“Fusion” or the “Company”) (NASDAQ: FUSN) in connection with its proposed acquisition by a subsidiary of AstraZeneca. Under the merger agreement, the Company’s shareholders will receive $21.00 per share at closing plus a non-transferable contingent value right (“CVR”) of $3.00 per share payable upon the achievement of a specified regulatory milestone.

Join Case →

April 4, 2024

Landos Biopharma, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Landos Biopharma, Inc. (“Landos” or the “Company”) (NASDAQ: LABP), in connection with its acquisition by AbbVie Inc. (NYSE: ABBV). Under the merger agreement, the Company’s shareholders will receive $20.42 per share plus one non-tradable contingent value right (“CVR”) per share with avalue of up to $11.14 per share, subject to the achievement of a clinical development milestone.

Join Case →

Where to find us?

new york

305 Broadway, 7th FI
New York, NY 10007
(212) 682-3025

california

8383 Wilshire Blvd., Suite 935
Beverly Hills, CA 90211
(310) 208-2800

georgia

476 Hardendorf Ave. NE
Atlanta, GA 30307
(404) 692-7910

NEW JERSEY

4 Brighton Rd, Suite. 204
Clifton, NJ 07012

Copyright 2022 Weiss Law. All rights reserved

Attorney AdvertisingLegal

Design by Cramdyn